MADRIGAL PHARMACEUTICALS INC (MDGL) Stock News

USA - Nasdaq - NASDAQ:MDGL - US5588681057 - Common Stock

582.93 USD

+3.04 (+0.52%)

Last: 12/4/2025, 12:49:13 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MDGL Latest News, Press Relases and Analysis

All

Press Releases

2 hours ago - By: Zacks Investment Research - Mentions: IONS

Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue?

a day ago - By: The Motley Fool - Mentions: MBX CGEM RNA TRVI ...

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

6 days ago - By: The Motley Fool - Mentions: MLTX CGEM RNA TRVI ...

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash

a month ago - By: Benzinga - Mentions: KURA SEE HRMY FOLD ...

Earnings Scheduled For November 4, 2025

a month ago - By: Benzinga

A Look Ahead: Madrigal Pharmaceuticals's Earnings Forecast

10 days ago - By: Stocktwits - Mentions: LLY

Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum

14 days ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

17 days ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

24 days ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

a month ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Zacks Investment Research - Mentions: BEAM FOLD ANIP

Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up

a month ago - By: Zacks Investment Research - Mentions: NAMS

Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates

a month ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

a month ago - By: Zacks Investment Research - Mentions: ECOR

Analysts Estimate electroCore, Inc. (ECOR) to Report a Decline in Earnings: What to Look Out for

a month ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

2 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Yahoo Finance

Leerink Partners Maintains a Buy on Madrigal Pharmaceuticals (MDGL), Here’s Why

3 months ago - By: Investor's Business Daily - Mentions: NVO LLY

Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure

3 months ago - By: Yahoo Finance

Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?

3 months ago - By: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)